KALA

KALA BIO, Inc. is a clinical-stage biopharmaceutical company focused on developing therapies for rare and severe eye diseases. The company's proprietary mucus-penetrating particle (MPP) technology platform enables enhanced drug delivery to ocular tissues. KALA BIO's pipeline includes treatments for diseases affecting the back of the eye, including geographic atrophy and other retinal disorders. The company is advancing multiple clinical programs aimed at addressing significant unmet medical needs in ophthalmology.